leisure time -WSS

leisure time

author：focus 2025-10-02 01:40:00 - browse：53

Adam's take main illustration — Molly Ferguson/STAT

MoonLake Immunotherapeutics, a Swiss biotech, was buried Monday under an avalanche of its own data spin.

It’s been awhile since I encountered a management team that speaks so arrogantly about the supposed supremacy of its own drug, but then fails to back up the talk with real data. MoonLake claimed its experimental antibody called sonelokimab delivered “landmark” results in a mid-stage study of psoriatic arthritis.

Landmark? That’s a strange way of describing the results of a clinical trial that showed sonelokimab topping a placebo — an easy hurdle — but failing to separate from an active treatment comparator, the generic drug adalimumab (known better as Humira).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： How to improve immunocompromised access to mAb treatments

WSS

Profiling embryos to choose those with higher IQs is almost a reality

Sanofi strikes deal with Novavax, boosting the vaccine maker

A preacher's new calling: Diversifying neuroscience research

Steward Health Care files for bankruptcy

Hospital chaplains balance Covid safety with patients’ spiritual needs

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

explore

leisure time

focus

Jerome Adams on the need for new antivirals for Covid

Allen Institute goes after foundational questions, CEO Costa says

Hollywood unions extend contract negotiations for actors

Medicare Advantage overpayments discussion gets experts fired up

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

First recipient of genetically engineered pig kidney has died

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

After gene therapy, two congenitally deaf children hear for the first time

In Memoriam: Notable people who died in 2023

First recipient of genetically engineered pig kidney has died

hotspot

Researchers on aging grapple with how to calculate biological age

Nonprofit, backed by Microsoft, to certify AI tools in health care

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

How to improve immunocompromised access to mAb treatments

Researchers on aging grapple with how to calculate biological age

Study: Adult vaccinations pay for themselves in societal benefits

leisure time

knowledge

focus

hotspot